Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.

You may also be interested in...



As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results

Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.

Analysts Weigh Gilead’s Future In HIV

Despite recent sell-off on R&D cost worries, competitors’ patent expiry and safety issues could help.

Analysts Weigh Gilead’s Future In HIV

Despite recent sell-off on R&D cost worries, competitors’ patent expiry and safety issues could help.

Related Content

Topics

UsernamePublicRestriction

Register

PS068101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel